Drug intelligence / Profile preview

PB 20X

Development stage: Preclinical
Lead developer: PB Immune Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PB 20X is a preclinical-stage therapeutic candidate being developed by PB Immune Therapeutics, a South Korean biotechnology company specializing in precision immunology. It belongs to the company's 200-series pipeline, which focuses on the development of bispecific antibodies for immuno-oncology applications. The program aims to leverage dual-targeting mechanisms to enhance the precision and efficacy of immune-mediated tumor destruction. According to company pipeline disclosures, PB 20X has completed initial proof-of-concept (PoC) validation and is currently undergoing preclinical studies, with a development timeline projected through 2026.

Beyond the preview

Go deeper on PB 20X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB 20X.

Explore the full profile